Regeneron deal may not reach such great heights
Regeneron is attempting to develop a monoclonal antibody that could be effective against future Covid-19 variants — suggesting that the agreement may be consequential if Regeneron succeeds.
Stay updated with breaking news from Research Corner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regeneron is attempting to develop a monoclonal antibody that could be effective against future Covid-19 variants — suggesting that the agreement may be consequential if Regeneron succeeds.
No prices have been set yet, much less the drugs that have been chosen for negotiation.
“Without requiring device shortage notifications outside of a PHE, our device supply chain and U.S. public health remain at risk,” Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, told POLITICO.
Earlier this year, the FDA granted the Alzheimer's drug, made by Eisai and Biogen, accelerated approval based on preliminary data.
Democratic leadership has expressed interest in developing another major spending bill, which could be another chance for lawmakers to tackle Medicare expansion and improved childcare measures.